Your browser doesn't support javascript.
loading
CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo.
Alajati, Abdullah; D'Ambrosio, Mariantonietta; Troiani, Martina; Mosole, Simone; Pellegrini, Laura; Chen, Jingjing; Revandkar, Ajinkya; Bolis, Marco; Theurillat, Jean-Philippe; Guccini, Ilaria; Losa, Marco; Calcinotto, Arianna; De Bernardis, Gaston; Pasquini, Emiliano; D'Antuono, Rocco; Sharp, Adam; Figueiredo, Ines; Nava Rodrigues, Daniel; Welti, Jonathan; Gil, Veronica; Yuan, Wei; Vlajnic, Tatjana; Bubendorf, Lukas; Chiorino, Giovanna; Gnetti, Letizia; Torrano, Verónica; Carracedo, Arkaitz; Camplese, Laura; Hirabayashi, Susumu; Canato, Elena; Pasut, Gianfranco; Montopoli, Monica; Rüschoff, Jan Hendrik; Wild, Peter; Moch, Holger; De Bono, Johann; Alimonti, Andrea.
  • Alajati A; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
  • D'Ambrosio M; Universita' della Svizzera Italiana, Lugano, Switzerland.
  • Troiani M; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
  • Mosole S; Universita' della Svizzera Italiana, Lugano, Switzerland.
  • Pellegrini L; Faculty of Biology and Medicine, University of Lausanne UNIL, Lausanne, Switzerland.
  • Chen J; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
  • Revandkar A; Universita' della Svizzera Italiana, Lugano, Switzerland.
  • Bolis M; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
  • Theurillat JP; Universita' della Svizzera Italiana, Lugano, Switzerland.
  • Guccini I; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
  • Losa M; Universita' della Svizzera Italiana, Lugano, Switzerland.
  • Calcinotto A; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
  • De Bernardis G; Universita' della Svizzera Italiana, Lugano, Switzerland.
  • Pasquini E; Faculty of Biology and Medicine, University of Lausanne UNIL, Lausanne, Switzerland.
  • D'Antuono R; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
  • Sharp A; Universita' della Svizzera Italiana, Lugano, Switzerland.
  • Figueiredo I; Faculty of Biology and Medicine, University of Lausanne UNIL, Lausanne, Switzerland.
  • Nava Rodrigues D; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
  • Welti J; Universita' della Svizzera Italiana, Lugano, Switzerland.
  • Gil V; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
  • Yuan W; Universita' della Svizzera Italiana, Lugano, Switzerland.
  • Vlajnic T; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
  • Bubendorf L; Universita' della Svizzera Italiana, Lugano, Switzerland.
  • Chiorino G; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
  • Gnetti L; Universita' della Svizzera Italiana, Lugano, Switzerland.
  • Torrano V; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
  • Carracedo A; Universita' della Svizzera Italiana, Lugano, Switzerland.
  • Camplese L; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
  • Hirabayashi S; Universita' della Svizzera Italiana, Lugano, Switzerland.
  • Canato E; Institute of Oncology Research (IOR), Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland.
  • Pasut G; Universita' della Svizzera Italiana, Lugano, Switzerland.
  • Montopoli M; Institute for Research in Biomedicine (IRB), Bellinzona, Switzerland.
  • Rüschoff JH; Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom.
  • Wild P; Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom.
  • Moch H; Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • De Bono J; Division of Clinical Studies, Institute of Cancer Research, London, United Kingdom.
  • Alimonti A; Royal Marsden NHS Foundation Trust, London, United Kingdom.
J Clin Invest ; 130(5): 2435-2450, 2020 05 01.
Article en En | MEDLINE | ID: mdl-32250342
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Moléculas de Adhesión Celular / Regulación Neoplásica de la Expresión Génica / Regulación hacia Arriba / Sistema de Señalización de MAP Quinasas / Antígenos de Neoplasias Límite: Animals / Humans / Male Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Moléculas de Adhesión Celular / Regulación Neoplásica de la Expresión Génica / Regulación hacia Arriba / Sistema de Señalización de MAP Quinasas / Antígenos de Neoplasias Límite: Animals / Humans / Male Idioma: En Año: 2020 Tipo del documento: Article